Zepbound® for Weight Loss
Tirzepatide for Weight Loss and Metabolic Health
Zepbound® (tirzepatide) is a once-weekly injection medication used for long-term weight management in appropriate patients with overweight or obesity.
Tirzepatide acts on two metabolic hormone pathways involved in appetite and glucose regulation and has shown in clinical trials to show roughly 12-20% of body mass over three years.
At Kass Precision Medicine, we consider medication within the larger context of body composition, cardiometabolic health, hormone health, nutrition, exercise, muscle preservation, and long-term weight maintenance.
What Is Zepbound?
Zepbound is the brand name for tirzepatide. Originally, it was released as a diabetes medication known as Mounjaro. This is a dual peptide medication activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These hormones are involved in appetite, satiety, glucose regulation, and energy metabolism. By acting on both pathways, tirzepatide can reduce hunger and food intake while improving glucose regulation. Zepbound is administered as a once-weekly injection.
How Does Zepbound Work?
REDUCES HUNGER SIGNALS
Acts on appetite-regulating pathways in the brain to reduce hunger and the drive to eat.
QUIETS “FOOD NOISE”
Helps reduce food cravings and preoccupation with food, making it easier to consume fewer calories.
INCREASES FULLNESS
Promotes satiety and slows gastric emptying, particularly earlier in treatment, so smaller amounts of food feel more satisfying.
IMPROVES GLUCOSE REGULATION
GIP and GLP-1 work together to increase glucose-dependent insulin secretion, improve glucose control, and support insulin sensitivity.
ACTIVATES TWO METABOLIC PATHWAYS
Unlike Wegovy, which targets GLP-1 alone, Zepbound also activates the GIP receptor. This dual action is thought to contribute to tirzepatide’s effects on appetite, glucose metabolism, and body weight.
How Is Zepbound Different From Wegovy?
Zepbound and Wegovy are both used for medical weight management, but they differ slightly in mechanism, formulation, and they each have their own additional FDA indications outside of weight loss.
DUAL GIP + GLP-1 ACTION
Zepbound is a dual-peptide medication, and it activates both GIP and GLP-1 receptors. Wegovy acts on the GLP-1 receptor alone.
SLEEP APNEA TREATMENT
Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults who are obese.
See the detailed Zepbound vs. Wegovy comparison ↓
ZEPBOUND LED TO SLIGHTLY GREATER WEIGHT LOSS COMPARED TO WEGOVY
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks.
Zepbound (tirzepatide): 20.2% average body-weight reduction
Wegovy (semaglutide): 13.7% average body-weight reduction
Is Zepbound the Same as Mounjaro?
Zepbound and Mounjaro contain the same active medication - tirzepatide - but are simply released under different names for different FDA-approved indications.
Mounjaro is used to treat type 2 diabetes. Zepbound is approved for chronic weight management in patients who are obese or overweight with comorbidities and for obese patients with moderate-to-severe obstructive sleep apnea.
The brand names are therefore not interchangeable, even though the underlying medication is the same.
Is Zepbound the Same as Tirzepatide?
Zepbound is the FDA-approved brand name for tirzepatide. Tirzepatide is the active medication or ingredient within Zepbound and affects GIP and GLP-1 receptors.
Tirzepatide may also be prescribed as a compounded medication in certain circumstances when a clinician determines that a patient has an individualized medical need that cannot be met by the commercially available product. Compounded medications are not FDA-approved and do not undergo the same premarket review as Zepbound.
For some patients, an appropriately prescribed compounded formulation may offer clinically useful flexibility, such as a dosage or formulation tailored to an individual medical need. The decision to use branded Zepbound or a compounded teripeptide medication should be made with an experienced clinician and, when compounding is appropriate, and filled by a licensed compounding pharmacy.
How Does Zepbound Work for Weight Loss?
Tirzepatide acts on both GIP and GLP-1 receptors, influencing several biological processes involved in weight regulation:
Reduces hunger and appetite
Increases satiety
Reduces food intake
Improves glucose regulation and insulin sensitivity
Slows gastric emptying, particularly earlier in treatment
For many patients, these effects make it easier to eat less without the persistent hunger that can make sustained weight loss difficult.
Medication does not replace nutrition, exercise, or other aspects of metabolic health. It changes some of the biological signals involved in appetite and weight regulation.
How Much Weight Can You Lose With Zepbound?
Individual response varies, but tirzepatide has produced substantial weight loss in clinical trials.
In the original SURMOUNT-1 trial, adults with obesity or overweight without diabetes lost an average of approximately 15% to 21% of their starting body weight over 72 weeks, depending on dose.
Longer-term research in participants with obesity and prediabetes demonstrated sustained weight reduction over three years of treatment.
Some people lose considerably more or less than these averages. Treatment response, tolerability, body composition, metabolic health, and the sustainability of the strategy are all important considerations.
Zepbound and Visceral Fat
For metabolic health, where weight is lost can matter as much as the number on the scale.
Tirzepatide has been shown to substantially reduce waist circumference, an important clinical marker of abdominal adiposity. In the direct SURMOUNT-5 comparison, average waist circumference decreased by 18.4 cm with tirzepatide over 72 weeks. Reducing excess abdominal and visceral fat can improve insulin sensitivity and other cardiometabolic risk factors.
The goal is not simply lower body weight.
It is improved body composition and metabolic health.
Zepbound and Prediabetes
Tirzepatide has also been studied over several years in people with obesity and prediabetes.
In a three-year analysis of SURMOUNT-1, participants receiving tirzepatide experienced sustained weight loss and were substantially less likely to progress from prediabetes to type 2 diabetes than participants receiving placebo.
These findings are particularly relevant when excess weight is accompanied by insulin resistance, elevated glucose, or other signs of metabolic dysfunction.
Weight Loss Shouldn’t Mean Losing Muscle
Significant weight loss can involve loss of both fat and lean tissue. Preserving skeletal muscle is particularly important in midlife and beyond.
Our approach emphasizes adequate protein intake, resistance training, appropriate nutrition, and thoughtful medication dosing to support muscle preservation while reducing excess fat.
The goal is better body composition - not simply lower body weight.
Zepbound and Obstructive Sleep Apnea
Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, in conjunction with a reduced-calorie diet and increased physical activity.
In clinical trials, tirzepatide reduced the frequency of breathing interruptions during sleep and also reduced body weight.
Sleep apnea is closely associated with metabolic and cardiovascular health and is an important consideration in patients with obesity, particularly when symptoms such as snoring, daytime fatigue, or poor-quality sleep are present.
How Does Zepbound Affect Women and Men?
Zepbound acts through the same GIP and GLP-1 pathways in women and men, but the clinical context can differ.
Zepbound is not a treatment for hormonal deficiency in either women or men. These issues should be evaluated independently when clinically relevant.
WOMEN
Perimenopause and menopause can contribute to increased abdominal fat and loss of lean mass. PCOS, insulin resistance, sleep, and other hormonal or metabolic factors may also influence weight and treatment goals.
MEN
Visceral abdominal fat, sleep apnea, and age-related loss of muscle are particularly relevant to metabolic health in men. When clinically indicated, testosterone deficiency and other hormonal or metabolic factors may also warrant evaluation.
What Can I Expect When Taking Zepbound?
The experience varies from person to person.
Many men notice less hunger, earlier fullness, smaller portions, and less interest in food as the dose is gradually increased.
Nausea, diarrhea, constipation, vomiting, abdominal discomfort, or reflux can occur, particularly during dose escalation. Gradual titration and adjustment based on response and tolerability are important.
Zepbound Side Effects and Safety
The most common side effects of Zepbound are gastrointestinal and may include:
Nausea
Diarrhea
Constipation
Vomiting
Abdominal discomfort
Indigestion or reflux
More significant adverse effects can occur and should be reviewed before treatment.
Zepbound carries a boxed warning regarding thyroid C-cell tumors observed in animal studies and should not be used in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Medical history, current medications, pregnancy considerations, gastrointestinal health, and other potential contraindications should be reviewed before starting treatment.
Who Is a Candidate for Zepbound?
Zepbound (i.e. tirzepitide) is approved for long-term weight management in adults with obesity, or adults with overweight plus at least one weight-related health condition, when appropriate.
Eligibility for a medication and the decision to use it are not necessarily the same thing.
We also consider:
Metabolic and cardiovascular risk
Body composition and visceral fat
Prediabetes or insulin resistance
Sleep apnea
Weight history and previous treatment
Current medications
Medical history and contraindications
Treatment goals and patient preference
For some patients, another medication - or a strategy that does not involve medication - may be more appropriate.
What Happens If You Stop Zepbound?
Weight regain after stopping tirzepatide is common because the biological signals involved in hunger and weight regulation can return when medication is discontinued.
That does not mean every patient must remain on the same medication or dose indefinitely. Long-term strategies may include continued therapy, individualized dosing, transitioning treatment, or carefully monitored discontinuation.
Planning for maintenance should begin before goal weight is reached.
How We Use Zepbound at Kass Precision Medicine
Zepbound is started at a low dose and increased gradually based on response and tolerability.
The goal is not necessarily to reach the highest possible dose. Dosing can be guided by weight trajectory, appetite, metabolic response, side effects, body composition, and overall health goals.
Nutrition, protein intake, resistance exercise, sleep, and other relevant metabolic or hormonal factors are addressed alongside medication.
START LOW → TITRATE THOUGHTFULLY → MONITOR RESPONSE → PRESERVE MUSCLE → PLAN FOR MAINTENANCE
Wegovy vs. Zepbound: A Closer Comparison
Active medication
Zepbound® – Tirzepatide
Wegovy® – Semaglutide
Mechanism
Zepbound® – GIP + GLP-1
Wegovy® – GLP-1
Formulation
Zepbound® – Once-weekly injection
Wegovy® – Injection or oral tablet
average weight loss*
Zepbound® – 20.2%
Wegovy® – 13.7%
FDA indication
Zepbound® – Moderate-to-severe OSA in adults with obesity
Wegovy® – Cardiovascular risk reduction in certain adults with established CVD and overweight or obesity
*SURMOUNT-5 compared maximum tolerated doses of injectable semaglutide and tirzepatide over 72 weeks in adults with obesity without diabetes. Average trial results do not determine which medication is appropriate for an individual patient. Medical history, treatment goals, cardiovascular and metabolic health, formulation, tolerability, and individual response all matter.
Zepbound at Kass Precision Medicine
Zepbound can be an effective treatment for appropriate patients, but medication is only one component of weight management.
Our approach considers body composition, metabolic health, nutrition, exercise, muscle preservation, medication response, and long-term maintenance throughout treatment.
Frequently Asked Questions About Zepbound
Is Zepbound the same as tirzepatide?
Zepbound contains tirzepatide. Tirzepatide is the active medication; Zepbound is the brand under which it is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
Is Zepbound the same as Mounjaro?
No. Both contain tirzepatide, but they have different FDA-approved indications. Mounjaro is used to treat type 2 diabetes, while Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in certain adults.
Does Zepbound come in pill form?
No. Zepbound is currently available only as a once-weekly injection.
There is no FDA-approved oral tirzepatide or Zepbound pill at this time. This differs from Wegovy, which has both injectable and oral semaglutide formulations.
How quickly does Zepbound start working?
Some people notice changes in hunger and satiety relatively early in treatment, but Zepbound is gradually titrated and weight loss typically occurs over many months. Response varies between individuals.
How much weight can I expect to lose with Zepbound?
In clinical trials, average weight loss with tirzepatide has approached 20% or more of starting body weight at higher doses in some study populations. Individual results vary substantially.
Is Zepbound more effective than Wegovy?
In the SURMOUNT-5 direct comparison, tirzepatide produced greater average weight loss than semaglutide: 20.2% versus 13.7% over 72 weeks.
Average weight loss is only one factor in medication selection. The appropriate treatment depends on medical history, goals, formulation, tolerability, and other clinical considerations.
Can Zepbound help with prediabetes?
Tirzepatide can improve glucose regulation and insulin sensitivity. In a three-year study of people with obesity and prediabetes, progression to type 2 diabetes occurred substantially less often among participants receiving tirzepatide than among those receiving placebo.
Can Zepbound treat sleep apnea?
Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, along with reduced-calorie nutrition and increased physical activity.
Will I lose muscle on Zepbound?
Some lean tissue can be lost during significant weight loss. Adequate protein, resistance training, appropriate nutrition, and attention to the rate and magnitude of weight loss can help preserve muscle.
Do I have to take Zepbound forever?
Not necessarily, but obesity and weight dysregulation are often chronic. Weight regain after discontinuing tirzepatide is common. Decisions about continuing, adjusting, transitioning, or discontinuing treatment should be individualized and accompanied by a long-term maintenance strategy.
Can Zepbound be used during pregnancy?
Zepbound is not used for weight loss during pregnancy. Pregnancy plans should be discussed before treatment, and tirzepatide should be discontinued if pregnancy occurs.
Is Zepbound appropriate if I only want to lose 10 or 15 pounds?
Zepbound has specific FDA eligibility criteria and is not intended simply for cosmetic weight loss. Whether medication is appropriate depends on BMI, weight-related health conditions, metabolic risk, medical history, and treatment goals.